Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model

Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model

Abstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop...

Full description

Bibliographic Details
Main Authors: Fariba Dorostkar, Arash Arashkia, Farzin Roohvand, Zabihollah Shoja, Mohsen Navari, Maryam Mashhadi Abolghasem Shirazi, Zahra Shahosseini, Mohammad Farahmand, Mohammad Sadegh Shams nosrati, Somayeh Jalilvand
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Infectious Agents and Cancer
Subjects:
Human papillomavirus
HPV vaccine
E7 oncoprotein
Stimulator of interferon genes
STING
CpG ODN 2395
Online Access:https://doi.org/10.1186/s13027-021-00346-7

Internet

https://doi.org/10.1186/s13027-021-00346-7

Similar Items